Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis

Vaccine

Volumn 28, Issue 27, 2010, Pages 4340-4347

  Guerrero, Gloria G ^a,b,c,d,e   Debrie, Ann Sophie ^a,b,c,d   Locht, Camille ^a,b,c,d  

^a INSERM U1019   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c LAMIH   (France)

^d UNIV LILLE   (France)

^e UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

Author keywords

BCG; HBHA; Mycobacterium tuberculosis; Newborns; Prime boost

Indexed keywords

BACTERIUM ANTIBODY; BCG VACCINE; CYTOKINE; GAMMA INTERFERON; HEPARIN BINDING HEMAGGLUTININ; INTERLEUKIN 12; MYCOBACTERIUM VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; IMMUNE RESPONSE; LUNG; MEMORY T LYMPHOCYTE; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TUBERCULOSIS;

ANIMALS; ANIMALS, NEWBORN; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-12; LECTINS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TRANSFORMING GROWTH FACTOR BETA; TUBERCULOSIS;

EID: 77952744996     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.062     Document Type: Article

References (41)

1. World Health Organization. Global tuberculosis control. Surveillance, planning financing (2007)
2. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guérin vaccination of newborn and infants in the prevention of tuberculosis: meta-analysis of the published literature. Pediatrics 96 (1995) 29-35
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 271 (1994) 698-702
4. Andersen P., and Doherty T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3 (2005) 656-662
5. Rodrigues L.C., Pereira S.M., Cunha S.S., Genser B., Ichihara M.Y., de Brito S.C., et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366 (2005) 1290-1295
6. Pathan A.A., Sander C.R., Fletcher H.A., Poulton I., Alder N.C., Beveridge N.E., et al. Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A, different boosting intervals and implications for efficacy trials. PLoS ONE 2 (2007) e1052
7. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia Ankara in humans. Nat Med 9 (2003) 729-735
8. McShane H., Pathan A.A., Sander C., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 68 (2004) 2948-2953
9. Williams A., Goonetilleke N.P., McShane H., Clark S.O., Hatch G., Gilbert S.C., et al. Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pig. Infect Immun 73 (2005) 3814-3816
10. Pethe K., Alonso S., Biet F., Delogu G., Brennan M.J., Locht C., et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412 (2001) 190-194
11. Musser J.M., Amin A., and Ramaswamy S. Negligible genetic diversity of Mycobacterium tuberculosis host immune system protein targets: evidence of limited selective pressure. Genetics 155 (2000) 7-16
12. Temmerman S., Pethe K., Parra M., Alonso S., Rouanet C., Pickett T., et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 10 (2004) 935-941
13. Masungi C., Temmerman S., Van Vooren J.P., Drowart A., Pethe K., Menozzi F.D., et al. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis 185 (2002) 513-520
14. Hougardy J.M., Schepers K., Place S., Drowart A., Lechevin V., Verscheure V., et al. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS ONE 2 (2007) e926
15. Locht C., Houghardy J.M., Rouanet C., Place S., and Mascart F. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis 86 (2006) 303-309
16. Parra M., Pickett T., Delogu G., Dheenadhayalan V., Debrie A.S., Locht C., et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 72 (2004) 6799-6805
17. Menozzi F.D., Rouse J.H., Alavi M., Laude-Sharp M., Muller J., Bischoff R., et al. Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 184 (1996) 993-1001
18. Guerrero G.G., Feunou F.P., and Locht C. The coiled-coil N-terminal domain of the heparin-binding haemagglutinin is required for the humoral and cellular immune responses in mice. Mol Immunol 66 (2008) 116-124
19. Ramshaw I.A., and Ramsay A.J. The prime boost strategy: exciting prospects for improved vaccination. Immunol Today 21 (2000) 163-165
20. Goonetillike N.P., McShane H., Hannan C.M., Anderson R.J., Brookes R., and Hill A.V.S. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacilli Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 173 (2003) 1602-1609
21. Capozzo A.V., Ramirez K., Polo J.M., Ulmer J., Barry E.M., Levine M., et al. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and all mediated immunity in the presence of maternal antibodies. J Immunol 176 (2006) 5671-5681
22. Lagranderie M., Balazuc A.M., Abolhassani M., Chavarot P., Nahori M.A., Thouron F., et al. Development of mixed Th1/Th2 type immune response and protection against Mycobacterium tuberculosis after rectal or subcutaneous immunization of newborn and adult mice with Mycobacterium bovis BCG. Scand J Immunol 55 (2002) 293-303
23. Rouanet C., Sebrie A.S., Lecher S., and Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 11 (2009) 995-1001
24. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 19 (2001) 3331-3346
25. Flynn J.L., and Chan J. Immunology of tuberculosis. Annu Rev Immunol 19 (2001) 93-129
26. Cooper A.M., Solache A., and Khader S.A. Interleukin-12 and tuberculosis: an old story revisited. Curr Opin Immunol 9 (2007) 441-447
27. Khader S., Pearl J., Sakamoto K., Gilmartin L., Bell G., Jelley-Gibbs D., et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol 175 (2005) 788-795
28. Feng C., Jankovic D., Kulberg M., Cheever A., Scanga C., Hieny S., et al. Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J Immunol 174 (2005) 4185-4192
29. Torchinsky M.B., and Blander J.M. T helper 17 cells: discovery, function, and physiological trigger. Cell Mol Life Sci 67 (2010) 1407-1412
30. + T cells responses upon vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8 (2007) 369-377
31. + T cells during Mycobacterium tuberculosis infection. J Immunol 177 (2006) 4662-4669
32. Pedrosa J., Saunders B.M., Appelberg R., Orme I.M., Silva M.T., and Cooper A.M. Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice. Infect Immun 68 (2000) 577-583
33. Umemura M., Yahagi A., Hamada S., Begum M.D., Watanabe H., Kawakami K., et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin Infection. J Immunol 178 (2007) 3786-3796
34. Abebe F., and Bjune G. Protective role of the antibodies in the M. tuberculosis infection. Clin Exp Immunol 157 (2009) 235-243
35. Lopez Y., Yero D., Falero-Diaz G., Olivares N., Sarmiento M.E., Sifontes S., et al. Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16 kDa protein in a model of progressive pulmonary infection. Int J Med Microbiol 15 (2009) 1229-1237
36. Betelli E., Carrier Y., Gao W., Korn T., Strom B.T., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 44 (2006) 235-238
37. H-17 cell-mediated pathology. Nat Immunol 8 (2007) 1390-1397
38. H-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8 (2007) 967-974
39. + T cells and protective memory against tuberculosis. Tuberculosis 87 (2007) 465-473
40. + T cells mediate IFN-gamma-independent control of M. tuberculosis infection both in vitro and in vivo. J Immunol 171 (2003) 4689-4699
41. Junqueira-Kipnis A.P., Turner J., Gonzalez-Juarrero M., Turner O.C., and Orme I.M. Stable T-cell population expressing an effector cell surface phenotype in the lungs of mice chronically infected with M. tuberculosis. Infect Immun 72 (2004) 570-575